News Articles

Real-world study shows using Giotrif®/Gilotrif® (afatinib) followed by osimertinib provides a median of 27.6... INGELHEIM, Germany -Friday 19 October 2018

(BUSINESS WIRE)-- Boehringer Ingelheim today announced results from GioTag, a real-world retrospective study which examined the impact of first-line Giotrif®/Gilotrif® (afatinib) followed by osimertinib, in epidermal growth factor receptor mutation-positive (EGFR M+) non-small cell lung cancer...

Results from Pradaxa® RE-SPECT ESUS® and RE-SPECT... -Monday 15 October 2018

Data from key trials will aid in increasing scientific understanding of ESUS and CVT RESPECT-ESUS is first randomised trial to investigate clinical profile of Pradaxa® vs ASA   (BUSINESS WIRE) -- Boehringer Ingelheim today announced that primary results from two key trials,...

New analysis estimates the positive impact of empagliflozin on prolonging life expectancy in adults with type 2 diabetes... -Wednesday 10 October 2018  

Survival estimates from the EMPA-REG OUTCOME® trial data demonstrate potential long-term benefit of empagliflozin (marketed as Jardiance®) on life expectancy of adults with type 2 diabetes and cardiovascular disease1   (BUSINESS WIRE) -- Today, the journal Circulation published...

Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient... -Wednesday 26 September 2018

(BUSINESS WIRE)-- Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make informed decisions on how to sequence treatments for patients with epidermal growth factor receptor...

Boehringer Ingelheim and Tsinghua University Team up to Develop Novel Treatment Approaches that Rally the Immune System... -Tuesday 4 September 2018

(BUSINESS WIRE)-- Boehringer Ingelheim and Tsinghua University in Beijing announce a collaboration aiming to research and develop immunological therapies for infectious diseases. Scientists will work in the Boehringer Ingelheim-Tsinghua University Joint Research Center for Immuno-Infection to...

Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford Biomedica Announce... -Monday 6 August 2018

(BUSINESS WIRE)-- Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium (GTC)—consisting of Imperial College London and the Universities of Oxford and Edinburgh—Imperial Innovations, and Oxford BioMedica (OXB) announce a global collaboration to develop a first-in-class,...

Boehringer Ingelheim launches the initiative In Reach Africa to address key healthcare infrastructure and access... -Thursday 2 August 2018  

(BUSINESS WIRE)-- Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, announced recently the launch of the ‘In Reach Africa’ program, an initiative aimed at facilitating quality and innovative human and animal healthcare access across the African continent. The...

Boehringer Ingelheim and Lilly announce Trajenta®’s CARMELINA® cardiovascular outcome trial met its... -Thursday 19 July 2018  

(BUSINESS WIRE)-- CARMELINA®1 (CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with type 2 diabetes at high vascular risk) met its primary endpoint, defined as time to first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal...

Boehringer Ingelheim Invests More Than €200 Million to Establish Strategic Production Center for Veterinary Public... -Tuesday 10 July 2018

(BUSINESS WIRE)-- Boehringer Ingelheim today announced an investment of more than €200 million into a new strategic production center for Veterinary Public Health. The company will establish the new site in the French Rhône-Alpes region, which is known as the European “vaccine valley”....

CHMP issues positive opinion to expand Jardiance®, Synjardy® and... -Monday 2 July 2018  

European labels for Jardiance®, Synjardy® and Glyxambi® expanded to include positive effects on cardiovascular and renal endpoints from landmark EMPA-REG OUTCOME® trial1 (BUSINESS WIRE) -- Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) announced today that the European...

Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin... -Monday 25 June 2018  

(BUSINESS WIRE) -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that both randomised controlled trials in the EASE phase III programme, investigating the use of empagliflozin in combination with insulin therapy in adults with type 1 diabetes, met their primary...

Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development... -Friday 22 June 2018

(BUSINESS WIRE)-- Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building...

Spiolto® Respimat® enables greater physical activity in people living with... -Wednesday 23 May 2018    

Data presented at American Thoracic Society meeting underpin the benefits of Spiolto® Respimat® for physical activity in COPD1,2 Study published in American Journal of Respiratory and Critical Care Medicine shows Spiolto® Respimat® improves exercise capacity in...

Efficacy and safety of OFEV® reinforced in new presentations at ATS 2018 -Tuesday 22 May 2018

New analysis of the INPULSIS® and TOMORROW trials suggests treatment with OFEV® (nintedanib) associated with reduced risk of death in patients with idiopathic pulmonary fibrosis Separate analysis of INPULSIS® trials showed association between lung function decline and worsening in...

Boehringer Ingelheim R&D Pushes to Transcend Disease Boundaries -Wednesday 25 April 2018

Promising first-in-class and potential medical breakthrough pipeline projects presented at R&D Press Conference 80 clinical and pre-clinical projects of which 65% have first-in-class and breakthrough potential Highlight: First-in-class monoclonal antibody shows potential in multiple...

Boehringer Ingelheim and Lilly Announce an Academic Collaboration with University of Oxford to Investigate the Effects... -Monday 16 April 2018  

(BUSINESS WIRE) -- Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced an academic collaboration with the University of Oxford. EMPA-KIDNEY will investigate the effects of empagliflozin on the progression of kidney disease and the occurrence of cardiovascular death, in...

Boehringer Ingelheim to invest €65 million in avian vaccines -Thursday 12 April 2018  

(BUSINESS WIRE) -- Six months after inaugurating its new French animal health headquarters in the heart of the Lyon-Gerland Biodistrict, Boehringer Ingelheim has confirmed its allegiance to the region by announcing that it is about to invest a further €65 million in the metropolitan...

Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering... -Thursday 5 April 2018

(BUSINESS WIRE) -- Boehringer Ingelheim and OSE Immunotherapeutics, a biotechnology company focused on the development of innovative immunotherapies, today announced a collaboration and exclusive worldwide collaboration and license agreement to jointly develop OSE-172, a SIRP-alpha antagonist...

Final results from landmark DYNAGITO® trial published in The Lancet Respiratory... -Thursday 29 March 2018      

Results enhance existing evidence base showing Spiolto® Respimat® improves symptom reduction and quality of life over Spiriva® Respimat®2,3,4,5,6 For media excluding the United States of America, Canada and the United Kingdom (BUSINESS WIRE) -- Boehringer Ingelheim today...

Three Leading Animal Health Companies Join Hands to Launch World-Class Vaccine Joint Venture Targeting Foot-and-Mouth... -Monday 26 March 2018

(BUSINESS WIRE) -- Shaanxi Meili Omni-Honesty Animal Health Co., Ltd., China’s world-class vaccine company targeting foot-and-mouth disease in swine, was launched on March 24th with a groundbreaking ceremony held at the Airport New City in Xi’an, capital city of Shaanxi Province. Meili...